These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115 [TBL] [Abstract][Full Text] [Related]
7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269 [TBL] [Abstract][Full Text] [Related]
9. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter? Markauskas A; Mogensen O; dePont Christensen R; Jensen PT Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461 [TBL] [Abstract][Full Text] [Related]
10. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H; Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446 [TBL] [Abstract][Full Text] [Related]
11. Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer. Di Donna MC; Cucinella G; Zaccaria G; Lo Re G; Crapanzano A; Salerno S; Giallombardo V; Sozzi G; Fagotti A; Scambia G; Laganà AS; Chiantera V Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672451 [TBL] [Abstract][Full Text] [Related]
12. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer. Qin L; Huang H; Chen M; Liang Y; Wang H J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567 [TBL] [Abstract][Full Text] [Related]
13. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. Bendifallah S; Body G; Daraï E; Ouldamer L Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191 [TBL] [Abstract][Full Text] [Related]
14. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Bian C; Yao K; Li L; Yi T; Zhao X Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168 [TBL] [Abstract][Full Text] [Related]
15. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer. Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235 [TBL] [Abstract][Full Text] [Related]
16. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076 [TBL] [Abstract][Full Text] [Related]
17. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands. Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older. Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442 [TBL] [Abstract][Full Text] [Related]
20. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate]. Segev Y; Gemer O; Auslender R; Lavie O Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]